Tablets & Capsules


Issue link:

Contents of this Issue


Page 9 of 51

8 October 2020 Tablets & Capsules C John Giannone, Ed Wyszumiala, Danita Broyles, and Joy Brown USP COVID-19's impact on FDA inspections and manufacturer risk quality assurance This article discusses the recent decreases in the FDA's manu- facturing inspections due to COVID-19 and explains how USP's programs and resources can help drug-product manu- facturers and ingredient suppliers manage potential quality risks in the global supply chain. OVID-19 has impacted virtually every industry, and drug manufacturing is no exception. While changes in the demand for certain drug products is reshaping the industry and capturing headlines, another issue permeat- ing the conversation is how the pandemic has disrupted the Food and Drug Administration's (FDA's) inspection process. As of August 11, 2020, the FDA reported more than 18,000 inspections of domestic and foreign pharma- ceutical manufacturers in 2019, the last year untouched

Articles in this issue

Archives of this issue

view archives of Tablets & Capsules - TC1020